Category Specific RSS

biotech

Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders

PANDAS and PANS are debilitating conditions characterised by distressing symptoms, ranging from rage to signs of obsessive compulsive disorder.

3 years ago

Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma

With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with…

3 years ago

Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24

A blue chip denotes the cream of the crop—the most put-together, high-quality company or share. So one can only imagine…

3 years ago

Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose…

3 years ago

Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis…

3 years ago

Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the…

3 years ago